Modality
Radioligand
MOA
CAR-T CD19
Target
IL-17A
Pathway
Complement
CholangiocarcinomaEoE
Development Pipeline
Preclinical
Feb 2018
→ Jul 2028
PreclinicalCurrent
NCT06260229
1,477 pts·Cholangiocarcinoma
2018-02→2028-04·Not yet recruiting
NCT04846826
394 pts·Cholangiocarcinoma
2021-10→2028-07·Recruiting
1,871 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-04-252.1y awayInterim· Cholangiocarcinoma
2028-07-102.3y awayInterim· Cholangiocarcinoma
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2028-04-25 · 2.1y away
Cholangiocarcinoma
Interim
2028-07-10 · 2.3y away
Cholangiocarcinoma
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06260229 | Preclinical | Cholangiocarcinoma | Not yet recr... | 1477 | UPCR |
| NCT04846826 | Preclinical | Cholangiocarcinoma | Recruiting | 394 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |